Collaboration agreed
The Swiss biotech Actelion Ltd have reached an agreement with the Japanese pharmaceutical company Nippon Shinyaku of Kyoto for the co-development of NS-304, a novel treatment for pulmonary arterial hypertension.
NS-304, is an orally available long acting prostaglandin I2 receptor agonist with vasodilating effects. The compound recently completed phase I trials in the UK.
Under the terms of the agreement Actelion will be responsible for global development and commercialisation of NS-304 outside Japan, and the two companies will co-develop and co-commercialise the compound in Japan. No financial details were disclosed.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
